Literature DB >> 18465064

[A case of granulomatous rosacea coinciding with the use of etanercept: no relapse with infliximab].

U M Winter1, R Treudler, U Paasch, M Sticherling, J C Simon.   

Abstract

A woman with psoriasis vulgaris and psoriatic arthritis developed granulomatous rosacea after four weeks of therapy with etanercept. When this agent was stopped, her skin lesions rapidly resolved with topical therapy, suggesting a causal relationship between the skin lesions and drug intake. To the best of our knowledge, this is the first report on rosacea as granulomatous cutaneous adverse drug reaction caused by etanercept. No relapse of skin changes appeared under extended and successful anti-psoriatic therapy with infliximab.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465064     DOI: 10.1007/s00105-008-1533-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  11 in total

1.  Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections.

Authors:  David Beenhouwer; Robert Wallis; Michael Broder; Daniel E Furst
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

2.  Granulomatous tattoo reaction in a patient treated with etanercept.

Authors:  C Bachmeyer; L Blum; B Petitjean; F Kemiche; E Pertuiset
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-04       Impact factor: 6.166

Review 3.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.

Authors:  Daniel E Furst; Robert Wallis; Michael Broder; David O Beenhouwer
Journal:  Semin Arthritis Rheum       Date:  2006-07-03       Impact factor: 5.532

4.  Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.

Authors:  H-H Lee; I-H Song; M Friedrich; A Gauliard; J Detert; J Röwert; H Audring; S Kary; G-R Burmester; W Sterry; M Worm
Journal:  Br J Dermatol       Date:  2007-03       Impact factor: 9.302

Review 5.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.

Authors:  Robert S Wallis; Stefan Ehlers
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

6.  Cat scratch disease during etanercept therapy.

Authors:  Sylvain Mathieu; Jean-François Vellin; David Poujol; Jean-Michel Ristori; Martin Soubrier
Journal:  Joint Bone Spine       Date:  2007-02-05       Impact factor: 4.929

7.  Reactivation of latent granulomatous infections by infliximab.

Authors:  Robert S Wallis; Michael Broder; John Wong; Albert Lee; Lalima Hoq
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

Review 8.  [Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service].

Authors:  Cendrine Cabou; Haleh Bagheri; Alain Cantagrel; Bernard Mazières; Jean-Louis Montastruc
Journal:  Therapie       Date:  2003 Sep-Oct       Impact factor: 2.070

9.  Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.

Authors:  April Deng; Valerie Harvey; Bahram Sina; David Strobel; Ashraf Badros; Jacqueline M Junkins-Hopkins; Allen Samuels; Mana Oghilikhan; Anthony Gaspari
Journal:  Arch Dermatol       Date:  2006-02

10.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

View more
  1 in total

1.  [Undesired cutaneous adverse drug reactions: What is new?].

Authors:  R Treudler; J C Simon
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.